Equities research analysts forecast that Mediwound Ltd (NASDAQ:MDWD) will report $650,000.00 in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Mediwound’s earnings, with the highest sales estimate coming in at $700,000.00 and the lowest estimate coming in at $540,000.00. Mediwound reported sales of $430,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 51.2%. The firm is scheduled to announce its next earnings report on Tuesday, February 20th.

According to Zacks, analysts expect that Mediwound will report full year sales of $650,000.00 for the current fiscal year, with estimates ranging from $2.51 million to $2.61 million. For the next financial year, analysts expect that the business will post sales of $7.26 million per share, with estimates ranging from $3.80 million to $9.83 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Mediwound.

A number of research firms have recently issued reports on MDWD. Jefferies Group set a $10.00 target price on Mediwound and gave the company a “buy” rating in a report on Friday, August 25th. Oppenheimer reissued a “buy” rating and issued a $10.00 target price on shares of Mediwound in a report on Monday, September 18th. Zacks Investment Research raised Mediwound from a “hold” rating to a “buy” rating and set a $5.75 target price on the stock in a report on Wednesday, October 4th. ValuEngine raised Mediwound from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Finally, Cowen began coverage on Mediwound in a report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Mediwound currently has a consensus rating of “Buy” and a consensus price target of $9.13.

Several institutional investors have recently bought and sold shares of MDWD. Renaissance Technologies LLC boosted its stake in shares of Mediwound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Mediwound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after buying an additional 12,522 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Mediwound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares in the last quarter. Nationwide Fund Advisors purchased a new stake in shares of Mediwound in the third quarter valued at approximately $1,538,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Mediwound in the third quarter valued at approximately $2,140,000. Hedge funds and other institutional investors own 29.46% of the company’s stock.

Mediwound (MDWD) opened at $4.55 on Wednesday. Mediwound has a twelve month low of $4.15 and a twelve month high of $8.25.

ILLEGAL ACTIVITY NOTICE: “$650,000.00 in Sales Expected for Mediwound Ltd (MDWD) This Quarter” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/20/650000-00-in-sales-expected-for-mediwound-ltd-mdwd-this-quarter.html.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.